Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Inclusion Criteria: Patients with compensated hepatic cirrhosis secondary to chronic hepatitis C who would meet all the inclusion criteria below and would not interfere with any of the exclusion criteria below. * Patients (regardless of gender) who can take contraceptive measures from date of informed consent to the end of follow-up * Patients who meet all the criteria below in the test/observation/ investigation in 30 days before the beginning of treatment. * Patients with quantitative HCV-RNA (+) * ALT \> 40 IU/L * Patients who are classified as Child-Pugh Classification A, and who do not have ascites or hepatic encephalopathy * Prothrombin Time \<=3.0 seconds prolonged, total bilirubin \<= 1.5 mg/dL or direct bilirubin \<= 0.7 mg/dL, Albumin \>= 3.0 g/dL * AFP within normal limits, AFP-L3 \<= 10%，PIVKA-II \<= 100 mAU/mL * Serum creatinine \<= upper limit of normal, creatinine clearance \>= 51 mL/minute * Patients with fasting blood glucose \< 110 mg/dL. * Thyroid-stimulating hormone within normal limits * Hemoglobin level \>= 12 g/dL，leukocyte count \>= 3,000/mm3，neutrophil count \>= 1,500 /mm3，platelet count \>= 80,000/mm3 * Patients who weighs more than 40 kg and not more than 100 kg within 60 days prior to registration * Patients who were diagnosed with liver cirrhosis (fibrosis score: F4) based on the liver biopsy performed within a year prior to registration and is able to provide with liver tissue sample. * Patients who between the ages of 20 and…